MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review To judge a number of intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Principal trial goals have been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, although one of https://alexisvgmqt.ziblogs.com/31020795/what-does-nemifitide-ditfa-mean